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Figure S1:  Compounds (300 μM) were tested against the protease domain of Human Recombinant TMPRSS2 
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2. Enzyme selectivity data of ZFH7116 (1), VD2173 (2), Camostat and Nafamostat 3 from a panel 43 serine 
and cysteine proteases. 
Table S1. Protease selectivity of ZFH7116 (1) and VD2173 (2). 
NA = not active; all data provided in supplementary material. 
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Volume (uL) Exact weight (mg) MW
VD2173 10 382 3.0 785.84
ZFH7116 10 349 3.2 918.00
The compound was tested in a 10-dose IC50 with a 3-fold serial dilution starting at 20 uM against 43 proteases.
Control compounds were tested in a 10-dose IC50 with 3-fold serial dilution starting at 10 uM*.
(*Start at different concentrations for some enzymes )
Compound fluorescence : Compounds exhibit no fluorescent background that could interfere with the assay.
The protease activities were monitored as a time-course measurement of the increase in fluorescence signal 
from fluorescently-labeled peptide substrate, and initial linear portion of slope (signal/min) was analyzed.
Data pages include slope, % Enzyme Activity (No inhibitor control as 100% Activity), curve fit, and IC50.
The obtained IC50 values are summarized in the table below.
(Curve fits were performed when the activities at the highest concentration of compounds were less than 65%.)
Summary Table:
Target:
1 Calpain 1 4.71E-08 E64
2 Caspase 1 2.92E-08 IETD-CHO
3 Caspase 2 5.47E-07 IETD-CHO
4 Caspase 3 1.07E-09 DEVD-CHO
5 Caspase 4 >2.00E-05 2.13E-06 IETD-CHO
6 Caspase 5 1.15E-08 IETD-CHO
7 Caspase 6 >2.00E-05 1.24E-08 DEVD-CHO
8 Caspase 7 2.31E-09 DEVD-CHO
9 Caspase 8 2.83E-09 IETD-CHO
10 Caspase 9 2.64E-08 IETD-CHO
11 Caspase 10 9.17E-09 IETD-CHO
12 Caspase 11 5.67E-07 IETD-CHO
13 Caspase 14 6.82E-08 WEHD-CHO
14 Cathepsin B 2.24E-07 7.33E-09 E64
15 Cathepsin C 1.18E-06 E64
16 Cathepsin G 4.04E-06 Chymostatin
17 Cathepsin H 1.04E-05 3.56E-08 E64
18 Cathepsin L 7.14E-06 1.24E-08 E64
19 Cathepsin S 1.99E-06 8.95E-08 1.73E-09 E64
20 Cathepsin V 1.00E-05 3.89E-09 E64
21 Chymase 1.01E-08 Chymostatin
22 Chymotrypsin >2.00E-05 1.41E-09 Chymostatin
23 Elastase 4.83E-09 Sivelestat
24 FVIIa 6.15E-06 2.54E-06 5.75E-08 PCI 27483
25 FXa 4.89E-07 8.66E-08 1.86E-06 Gabexate mesylate (GM)
26 FXIa 7.89E-09 1.60E-08 2.39E-07 Gabexate mesylate (GM)
27 Kallikrein 1 1.98E-05 2.28E-07 4.61E-06 Leupeptin
28 Kallikrein 5 3.27E-07 8.07E-08 4.94E-06 Gabexate mesylate (GM)
29 Kallikrein 7 4.31E-05 Gabexate mesylate (GM)
30 Kallikrein 12 5.85E-06 5.60E-07 9.43E-08 Gabexate mesylate (GM)
31 Kallikrein 13 1.47E-06 5.99E-07 1.22E-05 Gabexate mesylate (GM)
32 Kallikrein 14 4.86E-08 1.95E-08 6.51E-07 Gabexate mesylate (GM)
33 Matriptase 2 <1.02E-09 <1.02E-09 3.91E-07 Gabexate mesylate (GM)
34 Papain 2.67E-08 1.97E-05 2.40E-10 E64
35 Plasma Kallikrein 1.39E-08 2.34E-09 1.48E-07 Gabexate mesylate (GM)
36 Plasmin 1.73E-06 1.34E-07 2.65E-07 Gabexate mesylate (GM)
37 Proteinase A 7.59E-06 1.88E-06 2.44E-04 Leupeptin
38 Proteinase K 2.21E-08 5.19E-09 4.51E-08 Proteinase K inhibitor
39 Thrombin a 2.14E-07 1.33E-06 1.57E-06 Gabexate mesylate (GM)
40 Trypsin <1.02E-09 <1.02E-09 3.07E-08 Gabexate mesylate (GM)
41 Tryptase b2 1.10E-09 <1.02E-09 9.70E-09 Gabexate mesylate (GM)
42 Tryptase g1 2.34E-09 <1.02E-09 1.33E-08 Gabexate mesylate (GM)
43 Urokinase 5.01E-09 7.82E-06 2.44E-08 Gabexate mesylate (GM)
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Volume (uL) Exact weight (mg) MW
VD2173 10 382 3.0 785.84
ZFH7116 10 349 3.2 918.00
The compounds were tested in a 10-dose IC50 with a 3-fold serial dilution starting at 20 uM against 1 protease.
Control compounds were tested in a 10-dose IC50 with 3-fold serial dilution starting at 1 uM.
(*Start at different concentrations for some enzymes )
Compound fluorescence : Compounds exhibit no fluorescent background that could interfere with the assay.
The protease activities were monitored as a time-course measurement of the increase in fluorescence signal 
from fluorescently-labeled peptide substrate, and initial linear portion of slope (signal/min) was analyzed.
Data pages include slope, % Enzyme Activity (No inhibitor control as 100% Activity), curve fit, and IC50.
The obtained IC50 values are summarized in the table below.
(Curve fits were performed when the activities at the highest concentration of compounds were less than 65%.)
Summary Table:
Target:
1 Furin 1.10E-09 Furin Inhibitor 1
* Empty cells indicate no inhibition or compound activity that could not be fit to an IC50 curve
Control compound 
ID




3. Synthesis and NMR and HPLC-MS spectra of new compounds 2, 4-7, 19-21.
Synthesis of peptidyl ketobenzothiazoles (kbts), 4-7 
We have previously published methodology for the synthesis of the kbt peptide inhibitors 1. As shown in Scheme 
1, we first construct the tripeptide (e.g. 6) or tetrapeptide (e.g. 4) on the 2-chlorotrityl resin using standard 
Fmoc-solid phase peptide synthesis protocols including HBTU for amide bond coupling and 20% piperidine for 
Fmoc deprotection steps.  The peptide 
is then capped with an acetyl group 
using acetic anhydride. Cleavage of the 
2-chlorotrityl resin without removal of
the protecting groups is accomplished 
using HFIP, then H-Arg(Mtr)-kbt is 
installed with HATU or EDC/HOBt in 
DMF. Final deprotection of the amino 
acid sidechains using TFA:water:thioanisole (95:2.5:2.5 %v/v) generates the target compounds which are 
purified by reverse phase prep HPLC.  
Scheme S2. Cycloamide synthesis (2, 19 and 20) 
Cyclic peptide VD2173 (2) was synthesized following the generic procedure outlined in Scheme 2 in 
which is also used for the construction of 19 and 20. Synthesis of the tripeptide cyclization precursors 
are synthesized on Wang resin using standard Fmoc solid phase peptide synthesis (SPPS) using 2HBTU for 
coupling steps and 20% piperidine for Fmoc removal steps. After the final Fmoc deprotection, the tripeptide is 
acetylated and then the Asp and Lys protecting groups are removed with 4N HCl. Cyclization is performed 
using EDCI and HOBt on the resin followed by TFA cleavage, then a final HATU coupling 
Scheme S1. Synthesis of acyclic P4-P1 tetrapeptide ketobenzothiazoles (kbts), 4-7.  
with H-Arg-(Pbf)-kbt followed by Arg deprotection to give the cyclic peptides which are purified by reverse phase 
prep HPLC. 
 
Scheme S3. Synthesis of cyclic peptide aryl ether 21 
 
Compound 21 was prepared from Fmoc-allylglycine as shown in Scheme 3. N-Deprotection followed by 
esterification and acetylation gives Ac-allylglycine which is then coupled to H-Leu-OMe using EDC/HOBt. The 
resulting dipeptide ester is hydrolyzed with LiOH and then coupled to H-Tyr(Oallyl)-OMe once again with 
EDC/HOBt to yield the cyclization precursor.  Olefin metathesis cyclization is accomplished with Grubbs 2nd 
generation catalyst to give key aryl allyl ether cyclic peptide intermediate. Ester hydrolysis followed by amide 
coupling to H-Arg(Pbf)-kbt and final deprotection with TFA as before gives 21 which is purified by prep HPLC. 
 
General synthesis, purification, and analytical chemistry procedures.  Starting materials, reagents, and solvents 
were purchased from commercial vendors unless otherwise noted. 1H NMR spectra were measured on a Varian 
400 MHz NMR instrument. The chemical shifts were reported as δ ppm relative to TMS using residual solvent 
peak as the reference unless otherwise noted. The following abbreviations were used to express the 
multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad. High-performed liquid 
chromatography (HPLC) was carried out on GILSON GX-281 using Waters C18 5μM, 4.6*50mm and Waters Prep 
C18 5μM, 19*150mm reverse phase columns, eluted with a gradient system of 5:95 to 95:5 acetonitrile:water 
with a buffer consisting of 0.05% TFA. Mass spectra (MS) were performed on HPLC/MSD using electrospray 
ionization (ESI) for detection. All reactions were monitored by thin layer chromatography (TLC) carried out on 
Merck silica gel plates (0.25 mm thick, 60F254), visualized by using UV (254 nm) or dyes such as KMnO4, p-
Anisaldehyde and CAMA (Cerium Ammonium Molybdate or Hanessian's Stain). Silica gel chromatography was 
carried out on a Teledyne ISCO CombiFlash purification system using pre-packed silica gel columns (12g to 330g 
sizes). All compounds used for biological assays are greater than 95% purity based on NMR and HPLC by 
absorbance at 220 nm and 254 nm wavelengths. 
 
General procedure for synthesis of acyclic peptides1 
Solid phase peptide coupling and deprotection: Into a reaction vial (with a fritted glass filter) under nitrogen 
containing H-Leu-2-Cl trityl or H-Phe-2-Cl trityl resin (0.714 g, 0.5 mmol) was added DMF/CH2Cl2 (15/15 mL). The 
mixture was shaken at RT for 30 min and then filtered. The resin was washed with DMF (10 mL) 2 times. A 
mixture of Fmoc-AA-OH (2.5 mmol) in DMF (20 mL), HBTU (0.853 g, 2.25 mmol) and iPr2NEt (0.87 mL, 5 mmol) 
was stirred at RT for 10 min and then added to the resin. The resultant heterogeneous mixture was shaken at 
RT overnight and then filtered. The resin was washed with DMF (20 mL x 4), dried and then piperidine/DMF 
(20% v/v, 30 mL) was added. The mixture was shaken for 1-4 h at RT, then filtered and was washed with DMF 
(10 mL x 4). Following the Fmoc deprotection of the dipeptide, the dipeptide is carried on to the next step or 
coupling of another Fmoc-AA-OH is performed in an identical fashion as described above and then subsequently 
a final Fmoc deprotection to the tripeptide. 
Acetyl capping and cleavage from resin: The peptide-containing resin was suspended in 30 mL of 0.5 M Ac2O 
and 1 M iPr2NEt in DMF and shaken at RT for 1 h. The reaction was filtered, and resin washed with DMF (10 mL 
x 4) followed by CH2Cl2 (10 mL x 4). The resin was then suspended in 30 ml of 25% v/v HFIP/ CH2Cl2 and shaken 
for 1 h. The reaction was filtered, and the filtrate was concentrated and dried in vacuo. 
Coupling of Arg (Pbf)-kbt:HCl and final deprotection. To crude peptide acid (400 mg, 1.0 mmol) dissolved in dry 
DMF (10 mL) under a nitrogen atmosphere at 0 °C was added HATU (456 mg, 1.20 mmol) followed by stirring 
for 15 min. Next, Arg(Pbf)-kbt:HCl (638mg; 1.10 mmol) and iPr2NEt (0.87 mL, 5.0 mmol) were added to the 
reaction at 0 °C. The reaction was allowed to reach room temperature and then stirred for an additional 2-3 h. 
DMF was removed under vacuum and water (250 mL) was added to the residue. The precipitate formed was 
filtered and washed with water (2 x 50 mL) then dried under vacuum. The precipitate was suspended in 10 mL 
TFA/thioanisole/water (95:2.5:2.5 v/v/v) and stirred for2 h at RT. The solvent was removed, and cold ether (100 
mL) was added. The resulting precipitate was collected by centrifugation and the crude product was purified by 
HPLC (C18, 15 x 150 mm column; eluent: acetonitrile/water (0.05% TFA) to give the final compound. 
Ac-WFR-kbt, 8. 1H NMR (399 MHz, DMSO-d6) d ppm 1.48 (br. s., 1 H), 1.54 - 1.69 (m, 1 H), 1.74 (m, 4 H), 2.70 - 
2.89 (m, 2 H), 2.90 - 3.22 (m, 4 H), 4.37 - 4.74 (m, 1 H), 5.41 - 5.58 (m, 1 H), 6.86 - 7.10 (m, 4 H), 7.11 - 7.36 (m, 
8 H), 7.40 - 7.57 (m, 2 H), 7.62 - 7.76 (m, 2 H), 7.93 - 8.12 (m, 2 H), 8.22 - 8.34 (m, 2 H), 8.60 (t, J=7.59 Hz, 1 H), 
10.76 (s, 1 H).  ESI-MS [M+H]+ calcd for for C35H38N8O4S+ 667.28, found 667.5.  
Ac-dWFR-kbt, 13. 1H NMR (399 MHz, DMSO-d6) d ppm 1.56 - 2.07 (m, 6 H), 1.93 - 2.04 (m, 1 H), 2.52 - 2.81 (m, 
4 H), 2.96 - 3.08 (m, 1 H), 4.39 - 4.50 (m, 1 H), 4.57 - 4.70 (m, 1 H), 5.46 - 5.58 (m, 1 H), 6.90 - 7.09 (m, 4 H), 7.09 
- 7.36 (m, 8 H), 7.44 - 7.59 (m, 2 H), 7.62 - 7.76 (m, 2 H), 7.99 (d, J=7.79 Hz, 1 H), 8.28 (t, J=8.37 Hz, 2 H), 8.47 (d, 
J=8.95 Hz, 1 H), 8.63 (d, J=6.62 Hz, 1 H), 10.74 (s, 1 H).  ESI-MS [M+H]+ calcd for C35H38N8O4S+ 667.28, found 
667.5.  
Ac-QFR-kbt, 6. 1H NMR (400 MHz, DMSO-d6) d ppm 0.85 - 1.23 (m, 10 H), 1.23 - 1.49 (m, 4 H), 2.15 (dd, J=13.89, 
8.41 Hz, 1 H), 2.30 (dd, J=13.69, 6.26 Hz, 1 H), 2.37 - 2.48 (m, 2 H), 3.41 - 3.52 (m, 1 H), 3.79 - 3.89 (m, 1 H), 4.86 
- 4.96 (m, 1 H), 6.24 - 6.42 (m, 7 H), 6.84 (quin, J=7.53 Hz, 3 H), 7.33 (d, J=7.43 Hz, 1 H), 7.37 - 7.45 (m, 3 H), 7.73 
(d, J=7.04 Hz, 1 H).  ESI-MS [M+H]+ calcd for C29H36N8O5S+ 609.26, found 609.5. 
Ac-IQFR-kbt, 7. H NMR (400 MHz, DMSO-d6) d ppm 0.70 - 0.84 (m, 7 H) 1.00 - 1.14 (m, 1 H) 1.31 - 1.48 (m, 1 H) 
1.54 - 1.84 (m, 7 H) 1.84 - 2.13 (m, 7 H) 2.72 - 2.84 (m, 1 H) 2.95 - 3.07 (m, 1 H) 3.10 - 3.21 (m, 2 H) 4.08 (t, J=6.85 
Hz, 1 H) 4.12 - 4.21 (m, 1 H) 4.51 - 4.64 (m, 1 H) 5.45 - 5.55 (m, 1 H) 6.81 (br. s., 1 H)7.10 - 7.31 (m, 6 H) 7.49 - 
7.57 (m, 1 H) 7.64 - 7.74 (m, 2 H) 7.95 (t, J=9.00 Hz, 2 H) 8.15 (d, J=7.83 Hz, 1 H) 8.28 (t, J=8.61 Hz, 2 H) 8.56 (d, 
J=5.87 Hz, 1 H).  ESI-MS [M+H]+ calcd for C35H47N9O6S+ 722.34, found 722.6. 
Ac-GQFR-kbt, 4 (MM3122). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.51 - 1.69 (m, 3 H), 1.70 - 1.83(m, 2 H), 1.87 
(s, 3 H), 1.91 - 2.11 (m, 3 H), 2.71 - 2.86 (m, 1 H), 2.98 - 3.08 (m, 1 H), 3.11 - 3.22 (m, 2 H), 3.68 (d, J=5.48 Hz, 2 
H), 4.10 - 4.23 (m, 1 H), 4.55 (br. s., 1 H), 5.50 (br. s., 1 H), 6.80 (br. s., 1 H), 7.09 - 7.32 (m, 7 H), 7.53 (br. s., 1 
H), 7.63 - 7.75 (m, 2 H), 8.02 (d, J=8.22 Hz, 1 H), 8.09 - 8.21 (m, 2 H), 8.23 - 8.34 (m, 2 H), 8.52 (d, J=6.26 Hz, 1 
H).  ). ESI-MS [M+H]+ calcd for C31H39N9O6S+ , 666.28, found 666.50. 
Ac-PQFR-kbt, 5. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.87 - 1.54 (m, 19 H), 2.09 -2.24 (m, 1 H), 2.37 - 2.49 (m, 3 
H), 2.76 - 2.89 (m, 1 H), 2.96 - 3.09(m, 1 H), 3.35 - 3.57 (m, 2 H), 3.78 - 3.94 (m, 1 H), 4.90 (br. s., 1 H), 6.25 - 6.53 
(m, 6 H), 6.76 - 6.90 (m, 2 H), 7.23 (d, J=7.43 Hz, 1 H), 7.33 (d, J=7.83 Hz, 1 H), 7.37 - 7.48 (m, 2 H), 8.44 (d, 
J=5.48 Hz, 1H). ).  ESI-MS [M+H]+ calcd for C34H43N9O6S+ 706.31, found 706.50. 
H-dWFR-kbt, 14:
Boc-dWF-OMe: Boc-D-Trp-OH (1 g, 3.28 mmol) and HCl.Phe-OMe (0.708g, 3.28 mmol) was taken in dry 
dichloromethane (10 mL) under nitrogen atmosphere and the reaction mixture was cooled to 0 oC and N,N-
diisopropylethylamine (1.7 mL, 9.84 mmol) and propylphosphonic anhydride (1.9 mL, 3.28 mmol, 50% solution 
in EtOAc) were added to the solution drop wise respectively. The reaction mixture was then stirred at 25 oC 
under nitrogen atmosphere for 1 hour and the completion of the reaction was confirmed by LC-MS monitoring. 
On completion the reaction mixture was diluted with 10 mL dichloromethane and washed with 10% citric acid 
solution, saturated sodium bicarbonate solution and brine respectively. The organic layer was dried over sodium 
sulfate and concentrated under reduced pressure. The crude product was triturated with hexane to obtain the 
title product in pure form as a white solid. Yield: 1.3 g (92.8%). Chemical formula: C23H33N3O5, Exact Mass: 
465.55, MS(ESI): found: [M + Na]+, 488.58. 
Boc-dWF-OH: Boc-WF-OMe (0.130 g, 0.279 mmol) was taken in a 1:1 mixture of THF and water and LiOH.H2O 
(0.035g, 0.873 mmol) was added to it. The reaction mixture was stirred for 30 minutes at 25 oC and the 
completion of the reaction was confirmed by LCMS monitoring. On completion, the THF was evaporated under 
reduced pressure and the remaining water layer was cooled to 0 oC. The water layer was then brought to pH 6.5 
by slow addition of 0.5 M HCl solution in water. The crude product precipitates out on addition of HCl and it was 
isolated by filtration. The crude product was dried under reduced pressure and triturated with diethyl ether to 
obtain the pure title product in pure form as white solid. Yield: 0.102g (80%). Exact Mass: 451.21, MS(ESI): found: 
[M + H]+, 452.26. 
Boc-dWFR(Mtr)-kbt: Boc-dWF-OH (35 mg, .077 mmol) and HATU (43.9 mg, 0.115 mmol) was taken in dry DMF 
under nitrogen atmosphere and the reaction mixture was cooled to 0 oC. N,N-diisopropylethylamine (0.04mL, 
0.231 mmol) was then added drop wise to the reaction mixture and the reaction mixture was allowed to stir for 
15 minutes followed by addition of HCl.Arg(Mtr)-kbt (41.75 mg, .077 mmol). The reaction mixture was stirred 
for 12 hours at 25 oC under nitrogen atmosphere and the completion of the reaction was confirmed by LC-MS 
monitoring. On completion, the reaction mixture was diluted with EtOAc and washed with 10% citric acid 
solution, saturated sodium bicarbonate solution and brine respectively. The organic layer was dried over sodium 
sulfate and concentrated under reduced pressure. The crude product was directly taken to the next step without 
further purification. Chemical formula: C48H56N8O8S2, Exact Mass: 936.37, MS(ESI): found: [M + H]+, 937.17. 
H-dWFR-kbt (14):  Boc-dWFR(Mtr)-kbt (85 mg, crude product from previous step) was taken in 5 mL
TFA:thioanisole:H2O (95:2.5:2.5) and the reaction mixture was stirred for 6 hours at 25 oC. The completion of 
the reaction was confirmed by LC-MS monitoring. On completion, the reaction mixture was concentrated under 
reduced pressure and triturated with diethyl ether to obtain the crude product as brown solid. The crude 
product was then subjected to reverse phase semi-preparative HPLC (Stationary phase: C18 column, mobile 
phase: H2O-Acetonitrile with 0.1% TFA in each, 15-65% Acetonitrile in H2O gradient for 20 minutes) to obtain 
the pure title product Yield: 25 mg (42% over two steps). Chemical formula: C33H36N8O3S, 1H NMR (400 MHz, 
METHANOL-d4) δ ppm 8.21 (d, J = 6.65 Hz, 1H), 8.11 (d, J = 7.43 Hz, 1H), 7.57 - 7.67 (m, 4H), 7.12 - 7.36 (m, 10H), 
7.01 - 7.08(m, 2H), 6.84 (s, 1H), 3.48 (d, J = 1.96 Hz, 1H), 3.13 (d, J = 6.65 Hz, 4H), 3.01 - 3.07 (m, 1H), 2.75 - 2.84 
(m, 1H), 2.65 (s, 2H), 2.03 (s, 5H), 1.41(d, J = 8.61 Hz, 1H)Exact Mass: 624.26, MS (ESI): found: [M + H]+, 625.5. 
H-dWFR-kbt-COOH, 15: The title compound was synthesized using the same procedure as 14 using H-Arg(Mtr)-
kbt-COOH:HCl1. Yield: 24 mg (43% over two steps). Chemical formula: C34H36N8O5S, 1H NMR (400 MHz, 
METHANOL-d4) δ ppm 10.58 (br. s., 0H), 8.82 (s, 1H), 8.22 - 8.32 (m, 2H), 7.70 (dd, J = 8.02, 16.24 Hz, 0H), 7.57 
- 7.64 (m, 1H),7.37 (d, J = 6.26 Hz, 1H), 7.22 (d, J = 13.30 Hz, 0H), 7.11 - 7.18 (m, 2H), 7.02 - 7.10 (m, 1H), 5.55 -
5.67 (m, 1H), 4.47 - 4.58 (m, 0H), 4.35 (dd, J= 5.09, 10.17 Hz, 0H), 4.05 - 4.31 (m, 2H), 3.37 - 3.55 (m, 1H), 3.07 - 
3.27 (m, 3H), 2.65 (s, 1H), 2.18 (dd, J = 6.06, 13.11 Hz,1H), 1.57 - 1.95 (m,3H), 1.16 - 1.52 (m, 2H), 1.06 (td, J = 
7.14, 13.89 Hz, 1H), 0.91 - 1.00 (m, 2H), 0.65 - 0.81 (m, 6H) Exact Mass: 668.253, MS (ESI): found: [M + H]+, 669.5. 
Ac-Cyclo(DLK)-R- ketobenzothiazole (2, VD2173). Into a reaction vessel (with fritted glass for resin support) 
containing Fmoc-L-Lys(Boc) Wang resin (5 g, 1.7 mmol), DCM (40 mL) was added. The mixture was shaken at RT 
for 15 min and then filtered. To the dry resin was added piperidine/DMF (20% v/v, 40 mL) and the mixture was 
shaken for 30 min at RT, then filtered. The resin was washed with DMF (2 x 30mL) and DCM (2 x 30 mL). Fmoc-
Leu-OH (1.8 g, 5.1 mmol), HBTU (2.25 g, 5.95 mmol), iPr2NEt (1.31 g, 10.2 mmol), and DMF (50 mL) were added 
to the vessel and shaken for 12 h, then filtered. The resin was washed with DCM (2 x 40 mL) and DMF (2 x 40 
mL), then piperidine/DMF (20% v/v, 40 mL) was added and the reaction was shaken for 30 min at RT, then 
filtered. The resin washed with DCM (2 x 30 mL) and DMF (2 x 30mL). Fmoc-Asp(OtBu)-OH (2.10 g, 5.1 mmol), 
HBTU (2.25 g, 5.95 mmol), iPr2NEt (1.31 g, 10.2 mmol), and DMF (50 mL) were added to the vessel and shaken 
for 12 h, then filtered. The resin was washed with DCM (2 x 40 mL) and DMF (2 x 40 mL). The peptide resin was 
then suspended in a solution of Ac2O (1.04 g, 10.2 mmol), and iPr2NEt (3.07 g, 23.8 mmol) in 40 mL of DMF. The 
mixture was shaken at RT for 1-2 h, filtered and resin washed with DCM (2 x 40 mL) followed by DMF (2 x 40 
mL). To the resin was added 40 mL of dry 4M HCl in 1, 4-dioxane followed by shaking for 30-40 min. at RT. The 
reaction was filtered, and the resin washed with DCM (2 x 40 mL) followed by DMF (2 x 40 mL). EDCI (0.98 g, 5.1 
mmol), HOBt (0.78 g, 5.1 mmol), iPr2NEt (1.1 g, 8.5 mmol), and DMF (80 mL) were added to the resin and the 
resulting mixture was shaken for overnight at RT. The mixture was filtered and the resin and washed with DCM 
(2 x 40 mL) followed by DMF (2 x 40 mL). To the acetyl capped peptide resin was added TFA (2 x 35 mL) and 
shaken for 30 min. The mixture was filtered, and the resin washed with DCM (2 x 40 mL). The filtrate was 
concentrated, and cold ether was added to the residue yielding the crude product as a precipitate which was 
purified by flash chromatography to give an off-white sold (400 mg).  
The macrocyclic tripeptide acid (400 mg, 1.0 mmol) was dissolved in dry DMF (10 mL) under a nitrogen 
atmosphere at 0 °C and HATU (456 mg, 1.20 mmol) was added followed by stirring for 15 min, and then the 
addition of Arg(Pbf)-kbt:HCl ( 638mg;  1.10 mmol) and iPr2NEt (0.87 mL, 5.0 mmol) at 0 °C. The reaction is 
allowed to reach RT and then stirred for 2-3 h. The DMF was removed in vacuo and water (250 mL) was added 
to the resulting residue. The precipitate formed was filtered and washed with water (2 x 50 mL) and dried. To 
this precipitate was added 10 mL of TFA/thioanisole/water (95:2.5:2.5 v/v/v) and the mixture was stirred for 2 
h at RT. The solvent was removed, and then cold ether (100 mL) was added. The crude product was collected 
by centrifugation. The crude product was purified by HPLC (C18, 15 x 150 mm column; eluent: acetonitrile/water 
(0.05% TFA) to give the title compound as a white solid. Overall yield (20%).1H NMR (400MHz ,DMSO-d6) δ ppm 
= 8.51 (d, J = 6.7 Hz, 1 H), 8.26 (dd, J = 8.0, 15.1 Hz, 1 H), 7.98 (d, J = 7.4 Hz, 1 H), 7.93 - 7.83 (m, 2 H), 7.73 - 7.63 
(m, 2 H), 7.53 (br. s., 1 H), 5.44 - 5.33 (m, 1 H), 4.60 - 4.48 (m, 1 H), 4.29 - 4.18 (m, 1 H), 3.42 (br. s., 4 H), 3.19 - 
3.06 (m, 3 H), 2.96 (br. s., 1 H), 1.84 (s, 3 H), 1.78 - 1.69 (m, 1 H), 1.65 - 1.33 (m, 8 H), 1.23 - 1.07 (m, 2 H), 0.89 - 
0.74 (m, 7 H). ESI-MS [M+H]+ calcd for C31H46N9O6S+ 672.33, found 672.5. 
Ac-Cyclo(DQK)-R- ketobenzothiazole, 20. Synthesized like VD2173. Overall yield (30%).1H NMR (400MHz, 
DMSO-d6) δ ppm = 9.19 (s, 1 H), 8.98 - 8.81 (m, 2 H), 8.78 - 8.67 (m, 1 H), 8.60 - 8.50 (m, 1 H), 8.38 - 8.24 (m, 1 
H), 8.24 - 8.13 (m, 1 H), 7.89 - 7.81 (m, 1 H), 7.41 - 7.32 (m, 1 H), 7.29 - 7.11 (m, 1 H), 6.21 - 5.98 (m, 2 H), 5.25 - 
5.08 (m, 1 H), 4.94 - 4.82 (m, 1 H), 4.05 (br. s., 2 H), 3.79 (t, J = 6.1 Hz, 6 H), 3.15 – 3.04 (m, 6 H), 2.69 - 2.56 (m, 
3 H), 2.44 - 2.32 (m, 3 H), 2.04 (s, 3 H), 2.25 (br. s., 5 H). ESI-MS [M+H]+ calcd for C30H43N10O7S+ 687.30, found 
687.50. 
Ac-Cyclo(DMK)-R- ketobenzothiazole, 19. Synthesized like VD2173. Overall yield (27%). 1H NMR (400MHz, 
DMSO-d6) δ ppm = 8.54 (d, J = 6.3 Hz, 1 H), 8.31 - 8.07 (m, 2 H), 7.93 (d, J = 8.2 Hz, 1 H), 7.68 (br. s., 1 H), 7.49 
(br. s., 1 H), 5.40 (br. s., 1 H), 4.51 (br. s., 1 H), 4.22 (br. s., 1 H), 3.15 (br. s., 6 H), 2.00 (d, J = 1.2 Hz, 4 H), 1.88 - 
1.77 (s, 3 H), 1.58 (br. s., 3 H), 1.39 - 1.03 (m, 16 H). ESI-MS [M+H]+ calcd for C30H43N9O6S2+ 690.28, found 690.40. 
Ac-Cyclo(Allyl-Y)-R- ketobenzothiazole, 21. Fmoc-(L)-glycine (3.5 g, 10 mmol) stirred in 20% piperidine in DMF 
(20 mL) for 1 hr. Solvent was removed under reduced pressure, product triturated with DCM and hexanes (1:3), 
filtered the product and washed with hexanes, dried and used in the next reaction. Above material was dissolved 
in methanol (10 mL) and cooled the reaction to 0 °C followed by added thionyl chloride (2 mL) dropwise and 
stirred for 10 min and ice bath was replaced by a water bath, and the reaction mixture heated to ~50 °C for 3 hr 
while stirring. Removal of the solvent left a white residue which was washed with diethyl ether (100 mL) and 
collected by vacuum filtration to yield the amino acid methyl ester hydrochloride as a solid (1.7 g). Above ester 
(500 mg; 3.02 mmol) was taken in DCM (10 mL) and added DIEA (1.58 mL; 9.06 mmol) and Ac2O (0.86 mL; 9.06 
mmol) at RT and stirred for 3 hrs. Solvent was removed under reduced pressure and crude was purified by flash 
chromatography using EtOAc and Hexanes (1:9).  A solution of ester (395 mg; 2.5 mmol) in THF (3 mL) was 
treated with 1M aqueous LiOH (3 mL) and the reaction mixture was stirred for 3 h at RT, and the absence of 
starting material was monitored by TLC. After the solvent was evaporated off, the residue was diluted with 
water and the pH was adjusted to ~3.0 using 5% aq. HCl. The product was extracted with ethyl acetate (2 x 50 
mL) and the combined organic layer washe with brine (20 mL), dried over anhydrous Na2SO4, filtered off and 
concentrated, which is used in the next step without further purification. N-acetyl allyl glycine acid (167 mg; 
1.06 mmol) in DMF (5 mL) was stirred with peptide coupling reagent EDCI/HOBt or HATU (1.3 eq) for 30 min. 
The reaction was cooled to 0-5 °C and charged with amino acid methyl ester hydrochloride (1.1 eq.) followed by 
diisopropylethylamine (3.0 eq.). After 15 min, allowed the reaction was brought to RT and stirred overnight. 
Solvent was removed under reduced pressure and the residue partitioned between EtOAc and 5% aq. HCl. The 
separated organic layer was washed with aq. 5% HCl, saturated NaHCO3 solution (2x) and brine (1x) then dried 
over anhydrous Na2SO4. The crude product was purified by silica gel column chromatography using EtOAc and 
Hexanes (2:8). A solution of the ester (343 mg; 1.2 mmol) in THF (4 mL) was treated with 1M aqueous LiOH (4 
mL). The reaction mixture was stirred for 3 h at RT, and the absence of starting material was monitored by TLC. 
After the solvent was evaporated off, the residue was diluted with water and the pH was adjusted to ~3.0 using 
5% aq. HCl. The crude product was extracted into ethyl acetate (3 x 100 mL). The combined organic layers were 
washed with brine (25 mL) and dried over anhydrous Na2SO4. N-acetyl dipeptide acid (135 mg; 0.5 mmol) was 
stirred with EDCI (1.3 eq) and HOBt (1.3 eq) in DMF (3 mL) for 30 min. The reaction was cooled to 0–5 °C and H-
L- O-allyl Tyr-OMe. HCl  (130 mg: 0.55 mmol) followed by DIEA (3.0 eq). After 15 min, allowed the reaction to RT 
and stirred overnight. Solvent was removed under reduced pressure and the residue partitioned between EtOAc 
and 5% aq. HCl. The separated organic layer was washed with aq. 5% HCl, saturated NaHCO3 solution (2x) and 
brine (1x) then dried over anhydrous Na2SO4. The crude product was purified by silica gel column 
chromatography using EtOAc and Hexanes (3:7). 
A solution of acyclic diene precursor (150 mg, 0.3076 mmol) in DCM (280 mL, 0.2 Mol.) degassed for 30 min by 
purging nitrogen gas and then Grubbs 2nd generation catalyst (26 mg, 10 mol %) was added. The reaction was 
refluxed for 30 min and then additional Grubbs 2nd generation (13 mg, 5 mol %) was added. The reaction was 
refluxed for 18 h under nitrogen atmosphere. After depletion of the starting material as monitored by TLC and 
LCMS, the reaction was cooled to RT and quenched by adding activated charcoal (100 mg) followed by stirring 
for 1 h. The mixture was filtered through celite bed and washed generously with DCM. The filtrate was 
concentrated in vacuo and the crude product was purified by silica gel chromatography to yield an off-white 
solid. A solution of the macrocyclic ester (50 mg: 0.10 mmol) in MeOH (2 mL) was treated with 1M aq. LiOH (2 
mL) at RT for 3 hrs, and the absence of starting material was monitored by TLC. After the solvent was evaporated 
off, the residue was diluted with water and the pH was adjusted to ~3.0 using 5% aq. HCl. The product was 
extracted with ethyl acetate (3 x 50 mL) and the combined organic layer washe with brine (20 mL), dried over 
anhydrous Na2SO4, filtered off and concentrated, which is used in the next step without further purification. 
The macrocyclic acid (45 mg, 0.101 mmol) was dissolved in dry DMF (3 mL) under a nitrogen atmosphere at 0 
°C and HATU (50 mg, 1.30 mmol) was added followed by stirring for 15 min, and then the addition of Arg(Pbf)-
kbt:HCl ( 65 mg;  0.111 mmol) and iPr2NEt (70 uL, 0.404 mmol) at 0 °C. The reaction is allowed to reach RT and 
then stirred for 2-3 h. The DMF was removed in vacuo and water (250 mL) was added to the resulting residue. 
The precipitate formed was filtered and washed with water (2 x 50 mL) and dried. To this precipitate was added 
2.5 mL of TFA/thioanisole/water (95:2.5:2.5 v/v/v) and the mixture was stirred for 2 h at RT. The solvent was 
removed, and then cold ether (35 mL) was added. The crude product was collected by centrifugation. The crude 
product was purified by HPLC (C18, 15 x 150 mm column; eluent: acetonitrile/water (0.05% TFA) to give the title 
compound as a white solid. Overall yield (32%). 1H NMR (400MHz, DMSO-d6) δ ppm = 8.79 (d, J = 7.4 Hz, 1 H), 8.33 - 
8.25 (m, 2 H), 8.20 (d, J = 9.0 Hz, 1 H), 8.13 (d, J = 7.4 Hz, 1 H), 7.75 - 7.64 (m, 2 H), 7.53 (br. s., 1 H), 7.07 (d, J = 7.8 Hz, 2 
H), 6.67 (d, J = 7.8 Hz, 1 H), 5.60 - 5.36 (m, 2 H), 4.72 - 4.54 (m, 2 H), 4.37 - 4.25 (m, 1 H), 4.17 (br. s., 1 H), 3.16 (d, J = 6.3 
Hz, 2 H), 2.98 (d, J = 11.7 Hz, 3 H), 1.79 (s, 3 H), 1.64 (br. s., 4 H), 1.41 - 1.32 (m, 3 H), 1.24 - 1.14 (m, 4 H), 0.83 - 0.72 (m, 
10 H). 
The synthesis of 9, 10, 11, and 18 have been previously reported.2 
The synthesis of 1, 3, 12, 16, and 17 are as previously described.1  
NMR and HPLC-MS spectra of new compounds 2, 4-7,19-21. 
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VD2173 (Compound 2) 
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1H NMR (400 MHz, DMSO-d
6
) δ ppm 1.51 - 1.69 (m, 3 H) 1.70 - 1.83
(m, 2 H) 1.87 (s, 3 H) 1.91 - 2.11 (m, 3 H) 2.71 - 2.86 (m, 1 H) 2.98 -
3.08 (m, 1 H) 3.11 - 3.22 (m, 2 H) 3.68 (d, J=5.48 Hz, 2 H) 4.10 - 4.23
(m, 1 H) 4.55 (br. s., 1 H) 5.50 (br. s., 1 H) 6.80 (br. s., 1 H) 7.09 - 7.32
(m, 7 H) 7.53 (br. s., 1 H) 7.63 - 7.75 (m, 2 H) 8.02 (d, J=8.22 Hz, 1 H)
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1H NMR (400 MHz, DMSO-d
6
) δ ppm 0.87 - 1.54 (m, 19 H) 2.09 -
2.24 (m, 1 H) 2.37 - 2.49 (m, 3 H) 2.76 - 2.89 (m, 1 H) 2.96 - 3.09
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1H NMR (400 MHz, DMSO-d
6
) δ ppm 0.85 - 1.23 (m, 10 H) 1.23 - 1.49
(m, 4 H) 2.15 (dd, J=13.89, 8.41 Hz, 1 H) 2.30 (dd, J=13.69, 6.26 Hz, 1
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VD3173 (Compound 19) 
 
VD3152 (Compound 20) 
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VD4051 (Compound 21) 
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5. Figure S3. IC50 inhibition curves of full-length TMPRSS2/Boc-QAR-AMC (Data in Table 1). 
 
 















Figure S5. MM3122 acute toxicity study. 
NSG male and female mice (3 per group) 
were injected daily (IP) with 0, 20, 50, or 
100mg/kg MM3122 for 7 days. No changes 
in (a) body weight or (b) liver, spleen, or left 
or right kidney weights were observed. 
Statistical analysis was performed using 
one-way analysis of variance (ANOVA) 
compared to control animals with 
Dunnett’s multiple comparison test.  
Figure S4. Cell-based TMPRSS2 enzyme inhibition data of ZFH7116 (1) and VD2173 (2) in HEK-293 cells using 
Boc-QAR-AMC substrate. 






Figure S6. Inhibition of SARS-CoV-2 cell entry into Calu-3 lung epithelial cells by ZFH7116 
(1) and VD2173 (2) using VSV-SARS-CoV2-Spike protein Pseudotypes. EC50s are calculated 
from an average of 3 separate experiments. Camostat, an irreversible serine protease 
inhibitor, was used as a positive control. 
Figure S7. Inhibition of SARS-CoV-2 cell entry into Calu-3 lung epithelial cells by ZFH7116 
(1) and VD2173 (2) using VSV-SARS-CoV2-Spike protein Chimeras. EC50s are calculated 
from an average of 3 separate experiments. Camostat, a non-selective protease inhibitor, 
was used as a positive control. 





















Figure S8. Bacterial periplamic expression and purification of TMPRSS2-protease domain. (A) TMPRSS2-protease domain 
expression construct. N terminal fused pelB signalling peptide allows for secretion of the target protease to the periplasm allowing 
for correct folding and ease in purification downstream. (B) Michaelis-Menten curve of TMPRSS2-Protease domain against (MCA)-K-
KARSAFA-K-(DnP). Initial velocities of peptide cleavage were plotted against substrate concentration. Kinetic values were calculated 
using GraphPad Prism. (C) Denaturing SDS-PAGE gel of Ni-NTA affinity purification of TMPRSS2-Protase domain. Correct band size for 
TMPRSS2-protease domain (~26kDa) shown in Red arrow. (D) SDS-PAGE gel of size exclusion chromatography fractions. Fractions 
only containing protease domain were collected and pooled. E) Western blot against pooled TMPRSS2-protease domain. Blot using 
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